Effects of 2-methylthioadenosine 5'-β,γ-methylenetriphosphonate and 2-ethylthioadenosine 5'-monophosphate on human platelet activation induced by adenosine 5'-diphosphate

Drug Development Research

Volumn 38, Issue 1, 1996, Pages 12-23

  Hourani, Susanna M O ^a   Welford, Laurence A ^b,d   Cusack, Noel J ^c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ADERIS Pharmaceuticals Inc   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

2 Ethylthio AMP; 2 MeS AMP PCP; 2 Methylthio , methylene ATP; Adenylate cyclase; ADP analogs; AMP analogs; ATP analogs; Cyclic AMP; Human platelets; P(2T) purinoceptor agonists; P(2T) purinoceptor antagonists; P(2T) purinoceptors

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ADENYLATE CYCLASE; ADRENALIN; ARACHIDONIC ACID; CALCIUM; PURINE P2 RECEPTOR; RECEPTOR SUBTYPE; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NORMAL HUMAN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0029765524     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199605)38:1<12::AID-DDR2>3.0.CO;2-O     Document Type: Article

References (51)

1. Abbracchio MP, Burnstock G (1995): Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64:445-475.
2. Arunlakshana O, Schild HO (1959): Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Born GVR (1962): Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927-929.
4. Born GVR, Kratzer MAA (1984): Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol Lond 354:419-429.
5. Cattaneo MB, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM (1991): Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemostas 66:694-699.
6. Colman RW (1992): Platelet ADP receptors stimulating shape change and inhibiting adenylate cyclase. News Physiol Sci 7:274-278.
7. 2 receptor: Subclassification and structure-activity relationships. Drug Dev Res 28:244-252.
8. Cusack NJ, Hourani SMO (1981a): Partial agonist behaviour of adenosine 5′-O-(2-thiodiphosphate) on human platelets. Br J Pharmacol 73:405-408.
9. P diastereoisomers of adenosine 5′-O-(1-thiodiphosphate) on human platelets. Br J Pharmacol 73:409-412.
10. 1 of platelet aggregation induced by adenosine 5′-O-(1-thiodiphosphate) and adenosine 5′-O-(2-thiodiphosphate). Br J Pharmacol 75:257-259.
11. Cusack NJ, Hourani SMO (1982b): Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5′-monophosphate and adenosine 5′-triphosphate of human platelet aggregation induced by adenosine 5′-diphosphate. Br J Pharmacol 75: 397-400.
12. Cusack NJ, Hourani SMO (1982c): Adenosine 5′-diphosphate antagonists and human platelets: No evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol 76:221-227.
13. Cusack NJ, Hourani SMO (1982d): Competitive inhibition by adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate. Br J Pharmacol 77:329-333.
14. Cusack NJ, Pettey CJ (1988): Effects of isopolar isosteric phosphonate analogues of adenosine 5′-diphosphate (ADP) on human platelets. In Paton DM (ed): Adenosine and Adenine Nucleotides: Physiology and Pharmacology. London: Taylor & Francis, 287 pp.
15. 2T-purinoceptors mediating human platelet activation by ADP. Drug Dev Res 37:212-222.
16. 2-purinoceptors on guinea-pig taenia coli and urinary bladder. Br J Pharmacol 90:791-795.
17. Eckstein F, Goody RS (1976): Synthesis and properties of diastereoisomers of adenosine 5′-(O-1-thiotriphosphate) and adenosine 5′-(O-2-thiotriphosphate). Biochemistry 15:1685-1691.
18. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994): Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
19. Gachet C, Cattaneo M, Ohlmann P, Hechler P, Lecchi A, Chevalier J, Cassel D, Mannucci PB, Cazenave JP (1995): Purinoceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 91:434-444.
20. Gough G, Maguire MH, Penglis F (1972): Analogues of adenosine 5′-diphosphate - New platelet aggregators. Mol Pharmacol 8:170-177.
21. Gough G, Nobbs DM, Middleton JC, Penglis-Caredes F, Maguire MH (1978): New inhibitors of platelet aggregation. 5′-Phosphate, 5′-phosphorothioate, and 5′-sulfamoyl derivatives of 2-substituted adenosine analogues. J Med Chem 21:520-525.
22. 2T-purinoceptors on human platelets. Br J Pharmacol 108:728-733.
23. Hall DA, Hourani SMO (1994): Effects of suramin on increases of cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine diphosphate in human platelets. Biochem Pharmacol 48:1013-1018.
24. Hall DA, Frost V, Hourani SMO (1994): Effects of extracellular divalent cations on responses of human blood platelets to adenosine diphosphate. Biochem Pharmacol 48:1319-1326.
25. 2-purinoceptors: Subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 35:541-579.
26. Haslam RJ, Rosson GM (1975): Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11:528-544.
27. Haslam RJ, Davidson MML, Desjardins JV (1978): Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets: Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 176:83-95.
28. Heemskerk JWM, Sage SO (1994): Calcium signaling in platelets and other cells. Platelets 5:295-316.
29. Hourani SMO, Cusack NJ (1991): Pharmacological receptors on blood platelets. Pharmacol Rev 43:244-298.
30. Hourani SMO, Hall DA (1994): Receptors for ADP on human platelets. Trends Pharmacol Sci 15:103-108.
31. Hourani SMO, Hall DA (1996): P2T purinoceptors: ADP receptors on platelets. In Chadwick DJ, Goode JA (eds): P2 Purinoceptors: Localization, Function and Transduction Mechanisms (Ciba Foundation Symposium 198). Chichester: John Wiley & Sons, pp 52-59.
32. Hourani SMO, Welford LA, Cusack NJ (1986). 2-MeS-AMP-PCP and human platelets: Implications for the role of adenylate cyclase in ADP-induced aggregation? Br J Pharmacol 87:84P.
33. 2-purinoceptor antagonist suramin on human platelet aggregation induced by adenosine 5′-diphosphate. Br J Pharmacol 105:453-457.
34. 2T-purinoceptors. Br J Pharmacol 113:1057-1063.
35. 2T-purinoceptor antagonists: Definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 16:179-181.
36. 2T-purinoceptor antagonist, FPL 67085 in vitro and in the anesthetized rat in vivo. Br J Pharmacol 115:1110-1116.
37. Kenakin T (1995): Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
38. 2X purinoceptors be classified pharmacologically? Trends Pharmacol Sci 16:168-174.
39. Macfarlane DE, Mills DCB (1975): The effects of ATP on platelets: Evidence against the central role of released ADP in primary aggregation. Mol Pharmacol 11:528-544.
40. 32P]-diphosphate to the receptor on intact human platelets which inhibits adenylate cyclase. Biochem J 21:544-549.
41. 32P]-diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 71:420-428.
42. 2T purinoceptors in human platelets. J Biol Chem 271:2879-2881.
43. McClure MO, Kakker A, Cusack NJ, Born GVR (1988): Evidence for the dependence of arterial haemostasis on ADP. Proc R Soc Lond [Biol] 234:255-262.
44. i2 proteins. Biochem J 312:775-779.
45. Robertson MJ, Dougall IG, Harper D, McKechnie, Leff P (1994): Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model. Trends Pharmacol Sci 15: 364-369.
46. Sage SO, Mahaut-Smith MP, Rink TJ (1992): Calcium entry in non-excitable cells: Lesons from human platelets. News in Physiol Sci 7:108-113.
47. Schrör K (1993): Basic pharmacology of ticlopidine and clopidogrel. Platelets 4:252-261.
48. Tallarida RJ, Murray RB (1981): Manual of Pharmacologie Calculations. New York: Springer-Verlag.
49. 2-purinoceptor. Eur J Pharmacol 129:217-224.
50. 2X-purinoceptors: Evidence that dephosphorylation of ATP analogues reduces pharmacological potency. Eur J Pharmacol 141: 123-130.
51. 2 purinoceptors: An evolving family of novel therapeutic targets. Annu Rep Med Chem 31 (in press).